Biotech by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Biogen has the lowest figure of the 19 biotech ranked by P/S ratio, at 3.7, followed by Qiagen (4.9) and Neurocrine Biosciences (5.8). Figures as of 18 Nov 2026, 14:51 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 19
- Lowest
- Biogen3.7
- Median
- 14.5
- Combined market value
- ZAR 14.48T
- Countries
- 5
- Not ranked
- 5no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 3.7 | ZAR 637.3B | ZAR 4,311.18 | 0.10% down | 49% up | ||
| 2 | QiagenQGEN · Health Care | 4.9 | ZAR 176.5B | ZAR 854.92 | 0.13% down | 12% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 5.8 | ZAR 286.9B | ZAR 2,834.32 | 0.72% down | 20% up | ||
| 4 | BioNTechBNTX · Health Care | 6.6 | ZAR 361.3B | ZAR 1,457.25 | 0.20% down | 16% down | ||
| 5 | AmgenAMGN · Health Care | 6.6 | ZAR 4.18T | ZAR 7,734.14 | 1.85% down | 34% up | ||
| 6 | Gilead SciencesGILD · Health Care | 7.1 | ZAR 3.61T | ZAR 2,909.85 | 0.68% down | 33% up | ||
| 7 | ExelixisEXEL · Health Care | 7.2 | ZAR 287.9B | ZAR 1,179.70 | 0.09% up | 63% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | 7.8 | ZAR 188B | ZAR 1,649.19 | 0.13% down | 37% up | ||
| 9 | Bio-TechneTECH · Health Care | 9.4 | ZAR 196.6B | ZAR 1,251.46 | 0.14% up | 26% up | ||
| 10 | argenxARGX · Health Care | 14.5 | ZAR 1.04T | ZAR 16,479.02 | 1.07% up | 4% up | ||
| 11 | RepligenRGEN · Health Care | 14.7 | ZAR 187.3B | ZAR 2,930.07 | 5.00% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | 16.6 | ZAR 79.1B | ZAR 488.50 | 0.35% down | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | 20.5 | ZAR 133B | ZAR 1,950.23 | 1.20% up | 340% up | ||
| 14 | Krystal BiotechKRYS · Health Care | 23.1 | ZAR 154.5B | ZAR 5,215.14 | 1.52% up | 46% up | ||
| 15 | ModernaMRNA · Health Care | 42.1 | ZAR 1.41T | ZAR 3,484.48 | 2.08% down | 755% up | ||
| 16 | ImmunityBioIBRX · Health Care | 57.8 | ZAR 112.6B | ZAR 105.82 | 1.76% down | 193% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | 265 | ZAR 179B | ZAR 2,096.14 | 0.25% up | 87% up | ||
| 18 | CRISPR TherapeuticsCRSP · Health Care | 1144 | ZAR 69.1B | ZAR 712.02 | 3.06% up | 21% down | ||
| 19 | CG OncologyCGON · Health Care | 1726 | ZAR 120B | ZAR 1,343.08 | 1.12% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2069 ZAR). 5 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which biotech have the lowest P/S ratio?
Biogen (3.7), Qiagen (4.9) and Neurocrine Biosciences (5.8) have the lowest P/S ratio of the 19 biotech ranked here as of 18 Nov 2026, 14:51 UTC.
How many biotech are in this ranking?
19 are ranked by P/S ratio. 5 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these biotech worth together?
The 19 biotech ranked by P/S ratio have a combined market value of ZAR 14.48T as of 18 Nov 2026, 14:51 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.